文献速递心胸血管麻醉

体外循环中普通肝素给药的人群药代/药效学模型

Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass.
PubMed 文献 · Br J Anaesth · 2017-01-01

该研究在50例体外循环心脏手术患者中构建普通肝素的人群PK/PD模型,以抗Xa活性和ACT为效应指标,并开发贝叶斯估计器实现个体化给药。模型采用二室模型线性消除连接Emax模型,体重与清除率和中央室容积正相关;贝叶斯估计器在独立患者组中预测个体参数表现良好。

要点

  • 体重与肝素清除率和中央室容积正相关。
  • 贝叶斯估计器可仅用1–2个血样预测ACT。
  • 二室模型线性消除连接Emax模型拟合抗Xa与ACT。

核心结论

  • 基于常规凝血试验ACT的人群PK/PD分析显示,贝叶斯估计可能有助于仅用一至两个血样预测ACT。

研究设计与样本

  • 研究纳入50例接受体外循环心脏手术的连续患者,肝素初始推注300 IU kg-1,追加5000 IU维持ACT<400 s,共采集361份血样,采用非线性混合效应模型分析PK/PD数据。

主要发现

  • 二室模型线性消除连接Emax模型最能描述肝素抗Xa活性和ACT。
  • 体重与清除率和中央室容积正相关,纳入体重后两者变异性分别降低11%和15%。
  • 贝叶斯估计器在独立患者组中预测个体参数表现良好。

关键数值与推荐

  • 肝素初始推注300 IU kg-1,追加5000 IU维持ACT<400 s。
  • 体重纳入后清除率变异性降低11%,中央室容积变异性降低15%。

临床怎么用

  • 临床可考虑用贝叶斯估计器基于1–2个血样预测ACT,辅助体外循环中肝素个体化给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-dose heparin is used during cardiopulmonary bypass (CPB) to prevent thrombosis in the circuits used for extracorporeal circulation. The aim of this study was, initially, to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model to assess the variability of PK/PD parameters and their correlation with the results of the routine haemostatic test activated clotting time (ACT) and thereafter to develop a Bayesian estimator enabling an individualized dosing strategy. METHODS: Fifty consecutive patients undergoing cardiac surgery with CPB were included in the study. Heparin was administered as an initial bolus of 300 IU kg -1 followed by additional boluses of 5000 IU to maintain ACT <400 s. In total, 361 blood samples were collected. The PK and PD data were analysed using a non-linear mixed effect model. RESULTS: A two-compartment model with a linear elimination link to an E max model best described heparin anti-factor Xa activities and ACT. Covariate analysis showed that body weight was positively correlated with clearance and central compartment volume. Inclusion of body weight with these parameters decreased their variability by 11 and 15%, respectively. The Bayesian estimator performed well in predicting individual parameters in an independent group of patients. CONCLUSIONS: A population PK/PD analysis of heparin during CPB, using a routine haemostatic test, shows that Bayesian estimation might help to predict ACT on the basis of only one or two blood samples.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Delavenne X, Ollier E, Chollet S, et al. Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. Br J Anaesth. 2017. PMID: 28510738. doi:10.1093/bja/aex044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。